Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deal Details 14
Venture Financing 14
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Partnerships 17
Teva Pharma Enters into Licensing Agreement with Brain Resource 17
Teva Pharma Enters into Agreement with Syqe Medical 18
Teva Pharma Enters into Agreement with Intel 19
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 20
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 21
Teva Pharma Enters into an Agreement with Microchips Biotech 22
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 23
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 24
Equity Offering 25
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 27
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 29
American Well Raises USD10 Million in Private Placement of Shares 31
Debt Offering 32
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 32
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 34
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 36
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 38
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 40
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 42
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 44
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 46
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 48
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 52
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 54
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 56
Asset Transactions 57
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 57
Acquisition 59
Allergan to Sell 10% Stake in Teva Pharma 59
Teva Pharma Sells Stake in Mesoblast 60
Teva Pharma to Acquire Gecko Health Innovations 61
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 62
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 64
Teva Pharma Completes Acquisition of MicroDose Therapeutx 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
Biolin Scientific Acquires Sophion Bioscience 69
Clal Biotech Acquires Stake In TransPharma Medical From Teva 71
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 72
Teva Pharmaceutical Industries Ltd – Key Competitors 74
Teva Pharmaceutical Industries Ltd – Key Employees 75
Teva Pharmaceutical Industries Ltd – Locations And Subsidiaries 76
Head Office 76
Other Locations & Subsidiaries 76
Joint Venture 84
Recent Developments 85
Strategy And Business Planning 85
Oct 26, 2016: Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with Watson 85
Mar 31, 2016: Takeda and Teva Establish “Teva Takeda Yakuhin” in Japan 87
Feb 24, 2016: Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand 88
Financial Announcements 89
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 89
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 93
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 95
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 99
Jan 06, 2017: Teva Provides 2017 Financial Outlook 107
Nov 15, 2016: Teva Reports Third Quarter 2016 Results 109
Aug 04, 2016: Teva Reports Second Quarter 2016 Results 111
May 09, 2016: Teva Reports First Quarter 2016 Results 115
Feb 11, 2016: Teva Reports Full Year 2015 and Fourth Quarter Financial Results 119
Corporate Communications 125
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 125
Sep 19, 2017: Teva Completes Amendment to Credit Facilities 126
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 127
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 129
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 130
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 131
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 132
Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson 134
Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer 136
Jan 25, 2016: Teva Releases Innovation and Social Responsibility Highlights 137
Legal and Regulatory 138
Dec 22, 2016: Teva Reaches Settlement with Government on FCPA 138
Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 139
Other Significant Developments 140
Nov 27, 2017: Teva Announces New Organization Structure and Leadership Changes 140
Nov 21, 2017: Accelerating the Evolution of Pharma’s Digital Landscape – Practices from Viseven 143
Aug 31, 2016: Nanologica and Teva enter into a Feasibility Study Agreement 144
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 145
Appendix 146
Methodology 146
About GlobalData 146
Contact Us 146
Disclaimer 146
Teva Pharmaceutical Industries Ltd, Medical Equipment, Key Facts, 2016 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Teva Pharmaceutical Industries Ltd, Deals By Market, 2011 to YTD 2017 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Teva Pharma Enters into Licensing Agreement with Brain Resource 17
Teva Pharma Enters into Agreement with Syqe Medical 18
Teva Pharma Enters into Agreement with Intel 19
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 20
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 21
Teva Pharma Enters into an Agreement with Microchips Biotech 22
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 23
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 27
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 29
American Well Raises USD10 Million in Private Placement of Shares 31
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 32
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 34
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 36
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 38
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 40
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 42
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 44
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 46
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 48
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 52
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 54
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 56
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 57
Allergan to Sell 10% Stake in Teva Pharma 59
Teva Pharma Sells Stake in Mesoblast 60
Teva Pharma to Acquire Gecko Health Innovations 61
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 62
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 64
Teva Pharma Completes Acquisition of MicroDose Therapeutx 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
Biolin Scientific Acquires Sophion Bioscience 69
Clal Biotech Acquires Stake In TransPharma Medical From Teva 71
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 72
Teva Pharmaceutical Industries Ltd, Key Competitors 74
Teva Pharmaceutical Industries Ltd, Key Employees 75
Teva Pharmaceutical Industries Ltd, Subsidiaries 76
Teva Pharmaceutical Industries Ltd, Joint Venture 84